Jason A. Chesney, M.D., Ph.D.

Jason A. Chesney, M.D., Ph.D. Associate Professor of Medicine, Pharmacology and Toxicology, Biochemistry and Molecular Biology Deputy Director, James Graham Brown Cancer Center Associate Director, Translational Research Program, James Graham Brown Cancer Center Medical Director, Clinical Trials Office, James Graham Brown Cancer Center James Graham Brown Cancer Center 530 South Jackson Street Louisville, KY 40202 502-852-2522 - Academic Office 502-562-4370 - Patient Appointments

Clinical Expertise

Metastatic Melanoma; Refractory Solid Tumors; Clinical Trial Testing of Immunotherapeutics; Development of Anti-Metabolites as Targeted Chemotherapies

Education and Training

• Medical School: University of Minnesota

• Residency: Memorial Sloan-Kettering Cancer Center

• Fellowship: Cornell University Medical College

Recent Publications

• Liu Y, Sanchez-Tillo E, Lu X, Huang L, Clem B, Telang S, Jenson AB, Cuatrecasas M, Chesney J, Postigo A, Dean DC. Sequential Inductions of the ZEB1 Transcription Factor Caused by Mutation of Rb and then Ras are required for Tumor Initiation and Progression. J Biol Chem. 2013 Feb 26. [Epub ahead of print] PubMed PMID: 23443660.

• Ribas A, Chesney JA, Gordon MS, Abernethy AP, Logan TF, Lawson DH, Chmielowksi B, Glaspy JA, Lewis K, Huang B, Wang E, Hsyu PH, Gomez-Navarro J, Gerhardt D, Marshall MA, Gonzalez R. Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. J Transl Med. 2012 Nov 21;10:236. doi: 10.1186/1479-5876-10-236. PubMed PMID: 23171508; PubMed Central PMCID: PMC3543342.

• Clem BF, Chesney J. Molecular pathways: regulation of metabolism by RB. Clin Cancer Res. 2012 Nov 15;18(22):6096-100. doi: 10.1158/1078-0432.CCR-11-3164. PubMed PMID: 23154086.

• Telang S, Nelson KK, Siow DL, Yalcin A, Thornburg JM, Imbert-Fernandez Y, Klarer AC, Farghaly H, Clem BF, Eaton JW, Chesney J. Cytochrome c oxidase is activated by the oncoprotein Ras and is required for A549 lung adenocarcinoma growth. Mol Cancer. 2012 Aug 23;11:60. doi: 10.1186/1476-4598-11-60. PubMed PMID: 22917272; PubMed Central PMCID: PMC3546037.

• Telang S, Clem BF, Klarer AC, Clem AL, Trent JO, Bucala R, Chesney J. Small molecule inhibition of 6-phosphofructo-2-kinase suppresses t cell activation. J Transl Med. 2012 May 16;10:95. doi: 10.1186/1479-5876-10-95. PubMed PMID: 22591674; PubMed Central PMCID: PMC3441391.

• Akter S, Clem BF, Lee HJ, Chesney J, Bae Y. Block copolymer micelles for controlled delivery of glycolytic enzyme inhibitors. Pharm Res. 2012 Mar;29(3):847-55. doi: 10.1007/s11095-011-0613-4. Epub 2011 Oct 28. PubMed PMID: 22033882.

• Telang S, Rasku MA, Clem AL, Carter K, Klarer AC, Badger WR, Milam RA, Rai SN, Pan J, Gragg H, Clem BF, McMasters KM, Miller DM, Chesney J. Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma. BMC Cancer. 2011 Dec 13;11:515. doi: 10.1186/1471-2407-11-515. PubMed PMID: 22165955; PubMed Central PMCID: PMC3293785.

• Kim KB, Chesney J, Robinson D, Gardner H, Shi MM, Kirkwood JM. Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma. Clin Cancer Res. 2011 Dec 1;17(23):7451-61. doi: 10.1158/1078-0432.CCR-11-1747. Epub 2011 Oct 5. PubMed PMID: 21976540.

• Natarajan N, Telang S, Miller D, Chesney J. Novel immunotherapeutic agents and small molecule antagonists of signalling kinases for the treatment of metastatic melanoma. Drugs. 2011 Jul 9;71(10):1233-50. doi: 10.2165/11591380-000000000-00000. Review. PubMed PMID: 21770473.

• Chesney J, McMasters KM. Immunotherapy: Tumor-infiltrating T cells--ready for prime time in melanoma? Nat Rev Clin Oncol. 2011 Jul 5;8(8):449-50. doi: 10.1038/nrclinonc.2011.103. PubMed PMID: 21727931.